Home > Boards > US Listed > Biotechs > Portola Phramaceuticals (PTLA)

EPS beats by $0.34, beats on revenue

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H2R Member Profile
 
Followed By 22
Posts 1,757
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Termination of Registration of a Class of Security Under Section 12(b) (15-12b) Edgar (US Regulatory) - 7/13/2020 8:30:49 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/7/2020 3:40:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:56:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:55:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:46:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:41:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:38:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:38:12 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:35:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:29:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2020 5:29:23 PM
Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr) Edgar (US Regulatory) - 7/2/2020 2:33:20 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 7/2/2020 2:33:04 PM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ... Edgar (US Regulatory) - 7/2/2020 2:32:42 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 7/2/2020 2:31:38 PM
Post-effective Amendment to an S-8 Filing (s-8 Pos) Edgar (US Regulatory) - 7/2/2020 2:31:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2020 2:28:31 PM
Amended Tender Offer Statement by Third Party (sc To-t/a) Edgar (US Regulatory) - 6/25/2020 9:28:26 AM
Amended Statement of Ownership: Solicitation (sc 14d9/a) Edgar (US Regulatory) - 6/25/2020 9:27:20 AM
H2R   Tuesday, 11/05/19 05:47:31 PM
Re: None
Post # of 196 
EPS beats by $0.34, beats on revenue


Portola Pharmaceuticals (NASDAQ:PTLA):
* Q3 Non-GAAP EPS of -$0.53 beats by $0.34;
* GAAP EPS of -$0.68 beats by $0.20.
* Revenue of $36.8M (+159.2% Y/Y) beats by $2.16M.

https://seekingalpha.com/news/3514823-portola-pharmaceuticals-eps-beats-0_34-beats-revenue

That continues the positive trend on Andexxa and the balance sheet looks better.

Quote:
- Andexxa Now Stocked in Approximately 550 U.S. Hospitals; 76% of U.S. Sales from Reorders -
- Expanded Market Opportunity with Strong Initial Ondexxya Demand in Europe -
- Strengthened Balance Sheet; Added Net Proceeds of $245 million in Third Quarter -



A good quarter.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences